WAYNE, Pa. and PETACH TIKVA, Israel, July 20, 2011 /PRNewswire/ -- Molecular Detection Inc. (MDI), a company developing Detect-Ready® tests designed to increase the speed and accuracy of infectious disease diagnosis, and life sciences and diagnostics distributor Eldan, a part on the Neopharm Group, today announced that they have entered into an exclusive agreement for distribution of MDI's Detect-Ready MRSA Panel in Israel and the Palestinian territories. The Detect-Ready MRSA Panel is a qualitative real-time PCR in vitro diagnostic test that is marketed in the European Union (EU) and Australia and is in late-stage development in the US. The Detect-Ready MRSA Panel is CE-marked for the detection of MRSA (methicillin-resistant Staphylococcus aureus) and MSSA (methicillin-sensitive S. aureus) and is the only marketed PCR-based MRSA screening test with the proven ability to accurately discriminate between these pathogens and other related bacteria. This new agreement adds to MDI's growing global network of leading distribution partners.
This new distribution agreement follows MDI's announcement last week that it has received a notice of allowance from the US Patent and Trademark Office for a patent application covering a key aspect of its technology that accurately distinguishes between samples containing MRSA, MSSA and mixed populations of bacteria. The methods covered in the new patent, which are broadly applicable to all antibiotic-resistant bacteria, add legal backing to a growing body of independent data confirming that the Detect-Ready panel is the most technically advanced MRSA screening test available today.
"This agreement with Eldan extends our strategy of partnering our Detect-Ready MRSA Panel with major distributors in key territories around the globe," said Todd Wallach, CEO of MDI. "For over 50 years, Eldan has been providing high quality scientific and medical products to a
|SOURCE Molecular Detection Inc.|
Copyright©2010 PR Newswire.
All rights reserved